Influence of endogenous neuropeptide Y (NPY) on the sympathetic- parasympathetic interaction in the canine heart

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 4, 2005, Pages 474-480

  Ilebekk, Arnfinn ^a   Björkman, Jan Arne ^b   Nordlander, Margareta ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Heart rate; Neuropeptide Y; Norepinephrine; Pulse interval; Sympathetic stimulation; Vagal nerve stimulation

Indexed keywords

N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NEUROPEPTIDE Y; NORADRENALIN;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; FEEDBACK SYSTEM; HEART RATE; HEART STIMULATION; ISOLATED HEART; NEUROTRANSMITTER RELEASE; NONHUMAN; PARASYMPATHETIC INNERVATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; SYMPATHETIC TONE; VAGUS NERVE; VAGUS NERVE STIMULATION;

EID: 26044478415     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000177986.21929.d8     Document Type: Article

References (37)

1. Potter EK. Neuropeptide Y as an autonomic neurotransmitter. Pharmacol Ther. 1988;37:251-273.
2. Haass M, Cheng B, Richardt G, et al. Characterization and presynaptic modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropeptide Y in guinea pig heart. Naunyn Schmiedebergs Arch Pharmacol. 1989;339:71-78.
3. Lundberg JM, Franco-Cereceda A, Lacroix JS, et al. Neuropeptide Y and sympathetic neurotransmission. Ann NY Acad Sci. 1990;611:166-174.
4. Pernow J, Schwieler J, Kahan T, et al. Influence of sympathetic discharge pattern on noradrenaline and neuropeptide Y release. Am J Physiol. 1989;257:H866-H872.
5. Warner MR, Senanayake PD Jr, Ferrario CM, et al. Sympathetic stimulation-evoked overflow of noradrenaline and neuropeptide Y from the heart. Circ Res. 1991;69:455-465.
6. 1 receptor accounts for the long-lasting part of the sympathetic contraction in guinea-pig vena cava: evidence using SR 120107A. Acta Physiol Scand. 1995;155:329-330.
7. Franco-Cereceda A, Lundberg JM, Dahlof C. Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone. Acta Physiol Scand. 1985;124:361-369.
8. 2 receptor evidenced by BIIE0246. Eur J Pharmacol. 2002;439:113-119.
9. Potter EK. Prolonged non-adrenergic inhibition of cardiac vagal action following sympathetic stimulation: neuromodulation by neuropeptide Y? Neurosci Lett. 1985;54:117-121.
10. Potter E. Presynaptic inhibition of cardiac vagal postganglionic nerves by neuropeptide Y. Neurosci Lett. 1987;83:101-106.
11. 2) receptor. Eur J Pharmacol. 1994;267:253-262.
12. 2 receptors at peripheral neuroeffector junctions. Br J Pharmacol. 2001;132:861-868.
13. Warner MR. Time-course and frequency dependence of sympathetic stimulation-evoked inhibition of vagal effects at the sinus node. J Auton Nerv Syst. 1995;52:23-33.
14. Warner MR, Levy MN. Inhibition of cardiac vagal effects by neurally released and exogenous neuropeptide Y. Circ Res. 1989;65:1536-1546.
15. Smith-White MA, Wallace D, Potter EK. Sympathetic-parasympathetic interactions at the heart in the anaesthetized rat. J Auton Nerv Syst. 1999;75:171-175.
16. 2 receptors in modulation of cardiac parasympathetic neurotransmission. Regul Pept. 2002;103:105-111.
17. 2 receptor antagonist. Eur J Pharmacol. 1999;384:R3-R5.
18. 2 receptor antagonist. Br J Pharmacol. 2000;129:1075-1088.
19. Eriksson BM. Chromatography classic: Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection, by B.-M. Eriksson and B.-A., Persson, J Chromatogr, 228 (1982) 143.
20. J Chromatogr. 1993;612:1-5.
21. Theodorsson-Norheim E, Hemsen A, Lundberg JM. Radioimmunoassay for neuropeptide Y (NPY): Chromatographic characterization of immunoreactivity in plasma and tissue extracts. Scand J Clin Lab Invest. 1985;45:355-365.
22. Cousineau D, Goresky A, Bach GB, et al. Effect of β-adrenergic blockade on in vivo norepinephrine release in canine heart. Am J Physiol. 1984;246: H283-H292.
23. Lameris TW, Van den Meiracker AH, Boomsma F, et al. Catecholamine handling in the porcine heart: a microdialysis approach. Am J Physiol. 1999;277:H1562-H1569.
24. Haunstetter A, Haas M, Yi X, et al. Muscarinic inhibition of cardiac noradrenaline and neuropeptide Y release during ischemia and reperfusion. Am J Physiol. 1994;67:R1552-R1558.
25. Panidis IP, Morganroth J. Initiating events of sudden cardiac death. Cardiovasc Clin. 1985;15:81-92.
26. DeFerrari GM, Vanoli E, Schwartz PJ. (1995) Cardiac vagal activity, myocardial ischemia and sudden death. In Zipes DF, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: WB Saunders, 1995, pp 422-434.
27. La Rovere MT, Bigger JT Jr, Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet. 1998;351:478-484.
28. Schwartz PJ. Do animal models have clinical value? Am J Cardiol. 1998;81:14D-20D.
29. Schwartz PJ, LaRovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for postmyocardial infarction risk stratification. Circulation. 1992;85:I-77-99.
30. Binkley PF, Nunziata E, Haas GJ, et al. Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol. 1991;18:464-472.
31. Kinugawa T, Dibner-Dunlap ME. Altered vagal and sympathetic control of heart rate in left ventricular dysfunction and heart failure. Am J Physiol. 1995;268:R310-R316.
32. Pernow J, Lundberg JM, Kaiser L, et al. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin Physiol. 1986;6:561-578.
33. Morris MJ, Russell AE, Kapoor V, et al. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst. 1986;17:143-149.
34. Maisel AS, Scott NA, Motulsky HJ, et al. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med. 1989;86:43-48.
35. Solt VB, Brown MR, Kennedy B, et al. Elevated insulin, noradrenaline, and neuropeptide Y in hypertension. Am J Hypertens. 1990;3:823-828.
36. Gullestad L, Jörgensen B, Bjurö T, et al. Postexercise ischaemia is associated with increased neuropeptide Y in patients with coronary artery disease. Circulation. 2000;102:987-993.
37. 2 receptors in the postmortem human heart. Peptides. 2003;24:255-262.